Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of olopatadine hydrochloride ophthalmic solution 0.77% versus vehicle in asymptomatic eyes
2017-002728-26Phase 3
- Sponsor
- Alcon Inc.
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic conjunctivitis (AC) comparing Olopatadine hydrochloride ophthalmic solution 0.77% with Vehicle control (2 arms). Primary endpoint: Adverse events.
02
Drugs
olopatadine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on 2017-002728-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002728-26.